The study reported that GM-CSF KO did not impair CART proliferation and clinical efficacy of the treatment, and further the deficiency of TCR had no influence on its anti-tumor efficacy; results suggested long term persistence upon infusion and were indicative of re-expansion upon antigen exposure. The gene discussed is CSF2; the disease is neoplasm.